Table 1.
Description of study population
| Variablesa | Co-infected (n = 18) |
HIV infections alone (n = 18) |
|---|---|---|
| Demographic data | ||
| Sex, female (%, CI) | 11 (61.1) | 11 (61.1) |
| Age (median, IQR) | 36.5 (33.8–41.5) | 35.5 (30.8–45.2) |
| Clinical parameters | ||
| CD4+ (median/IQR) | 137 (35–197) | 125 (50–182) |
| WHO disease stage | ||
| 2 (n = 3) | 2 (11.1 %) | 1 (5.6 %) |
| 3 (n = 38) | 15 (83.3 %) | 13 (72.2 %) |
| 4 (n = 5) | 1 (5.6 %) | 4 (22.2 %) |
| ARV combination | ||
| d4T + 3TC + NVP (n = 8) | 4 (22.2 %) | 4 (22.2 %) |
| d4T + 3TC + EFV (n = 11) | 4 (22.2 %) | 3 (16.7 %) |
| CBV + NVP (n = 15) | 5 (27.8 %) | 6 (33.3 %) |
| CBV + EFV (n = 12) | 5 (27.8 %) | 5 (27.8 %) |
| Hepatitis virus markers | ||
| HBeAg | 10 (55.6 %) | – |
| Anti-HBe | 8 (44.4 %) | – |
| Anti-HBc IgM | 0 (0.0 %) | – |
aFor variable with n number of patients indicated, the percentages were calculated based on those values